Answers are grounded in this paper and cite their sources.
Sulfasalazine is widely prescribed for the peripheral manifestations of spondyloarthritis. Lupus-like reactions are a recognized but uncommon complication, and published series link renal involvement to prolonged treatment and high cumulative exposure. We report a 54-year-old man with axial and peripheral spondyloarthritis and computed tomography-confirmed bilateral structural sacroiliitis, in whom antinuclear antibodies, rheumatoid factor, anti-cyclic citrullinated peptide antibodies and extractable nuclear antigens were all negative and renal function, urinalysis and complement were normal before treatment. Approximately three weeks after sulfasalazine was started, at a cumulative dose of approximately 21 g, he developed a febrile diffuse truncal maculopapular eruption. Repeat serology showed de novo antinuclear antibodies at 1:640, anti-double-stranded DNA at 96 IU/mL, anti-Ro60, anti-Ro52 and anti-La/SSB antibodies, and hypocomplementemia. Sulfasalazine was withdrawn, but oliguric acute kidney injury followed, with a peak creatinine of 612 µmol/L, an active nephritic sediment, and a requirement for hemodialysis. Kidney biopsy demonstrated diffuse lupus nephritis, ISN/RPS class IV(A), with full-house immunofluorescence, subendothelial deposits on electron microscopy, an activity index of 8 of 24 and a chronicity index of 1 of 12, an almost purely acute lesion carrying no chronic damage. Causality assessment gave a Naranjo score of 7, in the probable range. After corticosteroids and a single two-infusion course of rituximab, renal function, complement and the entire autoantibody profile normalized within two months, and treatment-free clinical, renal and serologic remission persisted through 24 months. Reviewing the published experience, we find that the serologic phenotype of sulfasalazine-associated lupus differs from classic drug-induced lupus, anti-double-stranded DNA positivity being the rule rather than the exception, and that reported nephritis has been confined to patients with cumulative exposures exceeding 1,000 g. The present case, with severe biopsy-proven nephritis after an exposure roughly two orders of magnitude lower followed by complete serologic reversion, extends that spectrum and argues for urinalysis and renal monitoring from the earliest weeks of sulfasalazine therapy.
No takes yet. Share an insight, caveat, or question.
Najoua Ghani (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: